Zancong Shen Selected Research

lesinurad

1/2019	Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor.
1/2019	Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers.
1/2019	Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.
1/2018	The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
7/2017	Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
7/2017	Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide.
10/2016	Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
10/2016	Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
6/2016	In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters.
1/2016	Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zancong Shen Research Topics

Disease

22	Gout 11/2019 - 12/2014
13	Hyperuricemia 11/2019 - 10/2016
3	Neoplasms (Cancer) 01/2016 - 06/2011
1	Body Weight (Weight, Body) 01/2018
1	Melanoma (Melanoma, Malignant) 03/2013
1	Carcinoma (Carcinomatosis) 06/2011
1	Urinary Bladder Neoplasms (Bladder Cancer) 07/2008
1	Residual Neoplasm 07/2008
1	Hypoglycemia (Reactive Hypoglycemia) 07/2004

Drug/Important Bio-Agent (IBA)

20	Uric Acid (Urate)IBA 01/2019 - 12/2014
13	lesinuradIBA 01/2019 - 12/2014
9	verinuradIBA 11/2019 - 01/2017
8	Xanthine OxidaseIBA 01/2019 - 12/2014
3	Colchicine FDA LinkGeneric 01/2018 - 12/2014
3	Allopurinol (Remid)FDA LinkGeneric 01/2018 - 01/2018
2	BenzbromaroneIBA 01/2018 - 10/2016
2	Febuxostat FDA Link 01/2018 - 12/2014
1	AnticoagulantsIBA 01/2019
1	Warfarin (Coumadin)FDA LinkGeneric 01/2019
1	AntacidsIBA 01/2019
1	coumarinIBA 01/2019
1	Indomethacin (Indometacin)FDA LinkGeneric 07/2017
1	Naproxen (Naprosyn)FDA LinkGeneric 07/2017
1	Pharmaceutical PreparationsIBA 10/2016
1	urate transporterIBA 10/2016
1	Probenecid (Benemid)FDA LinkGeneric 10/2016
1	N- (3,4- difluoro- 2- (2- fluoro- 4- iodophenylamino)- 6- methoxyphenyl)- 1- (2,3- dihydroxypropyl)cyclopropane- 1- sulfonamideIBA 01/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2016
1	Sorafenib (BAY 43-9006)FDA Link 01/2016
1	Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA 03/2013
1	Small Interfering RNA (siRNA)IBA 06/2011
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2011
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 07/2008
1	Insulin (Novolin)FDA Link 07/2004
1	Blood Glucose (Blood Sugar)IBA 07/2004

Therapy/Procedure

7	Therapeutics 01/2018 - 07/2008
1	Immunotherapy 07/2008
1	Subcutaneous Injections 07/2004